摘要
生长刺激表达基因2蛋白(ST2)是白细胞介素1受体/Toll样受体超家族的成员,主要分为可溶性ST2(sST2)和跨模型ST2(ST2L)两种类型,白细胞介素33(IL-33)是其内源性配体。IL-33/ST2L通路具有抗动脉粥样硬化、抗心肌肥厚、抗心肌纤维化等多种心血管保护作用,而sST2作为一种诱骗受体,与IL-33结合则可以阻断上述生物学作用。近来研究发现,sST2作为一种新型生物标志物,在多种心血管疾病的诊治中发挥重要作用。本文将对sST2在冠心病及心力衰竭中的临床研究及进展做一综述。
The growth stimulation expression gene 2 protein(ST2)is a member of the interleukin 1 receptor/Toll-like receptor superfamily with two main types,soluble ST2(sST2)and ligand ST2(ST2L)and interleukin 33(IL-33)is its endogenous ligand.IL-33/ST2L pathway has a variety of cardiovascular protective effects such as anti-atherosclerosis,anti-myocardial hypertrophy and anti-myocardial fibrosis,while sST2,as a decoy receptor,can block these biological effects by binding to IL-33.Recent studies have found that sST2,as a novel biomarker,plays an important role in the diagnosis and treatment of a variety of cardiovascular diseases.Thus,this paper will review the clinical application and research progress of sST2 in coronary heart disease and heart failure.
作者
刘元值
金春子
高立建
赵光贤
Liu Yuanzhi;Jin Chunzi;Gao Lijian;Zhao Guangxian(Department of Cardiology,Yanbian University Hospital,Yanji 133099,China;Coronary Artery Disease Treatment Center,Fuwai Hospital,State Key Laboratory of Cardiovascular Disease,National Center for Cardiovascular Diseases,Beijing 100037,China)